Abstract: A compound effective in prevention and treatment of arteriosclerosis with a mechanism different from that of statin drugs has the following formula or a pharmaceutically acceptable salt, solvate, or hydrate thereof: wherein R1 is an aliphatic, alicyclic, or aromatic acyloxy group, or a group of the formula —O—CH(R7)—R8 where R7 is a lower alkoxy group and R8 is an aryl group, and R2 is carboxyl, a lower alkoxycarbonyl group, or an arylmethylcarbamoyl group, or a —CH2-acyloxy group and R3 is an aliphatic, alicyclic or aromatic acyloxy group, provided that at least one of R4 and R3 is a group other than acetoxy, or R2 and R3 taken together form a group of the formula —O—CH(R5)—O— where R5 is an aryl group.

Abstract: The present invention accurately predicts postoperative intraocular lens position on the basis of a shape image of the crystalline lens obtained by an optical interference tomographic imaging device. This makes it possible to reduce the postoperative refractive error and determine the power of the intraocular lens. The present invention comprises: a step for finding by computer the equatorial position, which is the site of maximum diameter in the crystalline lens, from the morphology of the crystalline lens obtained from a tomographic image of the patients eye generated by the optical interference tomographic imaging device; and a step for estimating the position of the intraocular lens from the equatorial position thus found.

Abstract: Provided is a growth factor anchoring type bone graft material, wherein a bone graft substrate exposing at least a collagen fiber is bound to a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide. The same can be produced by mixing a bone graft substrate and a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide, and is also superior in osteogenic ability.

Abstract: Proteins respectively having the amino acid sequences represented by SEQ ID NOs: 1, 17 and 32; structural genes respectively encoding the proteins, preferably respectively having the nucleotide sequences represented by SEQ ID NOs: 2, 18 and 33; an antibody capable of specifically binding to feline-derived cystatin C, feline-derived ?2 microglobulin or feline-derived ?1 microglobulin; a kit for diagnosing feline nephropathy, containing the antibody of the present invention; and a method for diagnosing feline nephropathy using the antibody of the present invention.

Abstract: (Problem to be Solved) There is to be provided a method for extracting low-molecular-weight proteins/peptides contained in a body fluid sample, particularly, in serum or plasma. (Means for Solution) The method according to the present invention comprises the steps of (a) to (e): (a) adding reagent 1 containing urea and thiourea and reagent 2 containing a reducing agent to the body fluid sample, mixing them, subsequently dropping the mixture into reagent 3 containing 90% or more of an organic solvent, and mixing them; (b) stirring at a low temperature the mixed solution obtained in step (a); (c) centrifuging at a low temperature the stirred solution obtained in step (b) and removing the supernatant; (d) adding reagent 4 containing an organic solvent and an acid to the precipitate obtained in step (c) and mixing them; (e) stirring at a low temperature the mixed solution obtained in step (d); and (f) centrifuging at a low temperature the stirred solution obtained in step (e) and recovering the supernatant.

Abstract: The object of the present invention is to provide a method for detecting gastric cancer, and a kit for detecting gastric cancer. The object can be solved by a method for detecting gastric cancer characterized by analyzing ?1,4-N-acetylgalactosamine transferase 1. According to the present invention, gastric cancer patients can be detected at high rates, even early stage gastric cancer patients without a subjective symptom.

Abstract: Treatment for alleviating ischemia-reperfusion injury which has minimized risk of side effects and which can suppress neutrophilic infiltration and activation of platelets during ischemia reperfusion comprises administration by inhalation of a mixed gas comprising 21%-98% oxygen, 0.1%-4% hydrogen, 40-80 ppm nitrogen monoxide, and a remainder of inert gas such as nitrogen or helium to a patient undergoing reperfusion from immediately before the start of ischemia reperfusion until shortly after the start of reperfusion.

Abstract: A compound effective in prevention and treatment of arteriosclerosis with a mechanism different from that of statin drugs has the following formula or a pharmaceutically acceptable salt, solvate, or hydrate thereof: wherein R1 is an aliphatic, alicyclic, or aromatic acyloxy group, or a group of the formula —13—O—CH(R7)—R8 where R7 is a lower alkoxy group and R8 is an aryl group, and R2 is carboxyl, a lower alkoxycarbonyl group, or an arylmethylcarbamoyl group, or a —CH2-acyloxy group and R3 is an aliphatic, alicyclic or aromatic acyloxy group, provided that at least one of R4 and R3 is a group other than acetoxy, or R2 and R3 taken together form a group of the formula —O—CH(R5)—O— where R5 is an aryl group.

Abstract: A method for extracting low-molecular-weight proteins/peptides contained in a body fluid sample, particularly, in serum or plasma. The method includes the steps of (a) to (e): (a) adding reagent 1 containing urea and thiourea and reagent 2 containing a reducing agent to the body fluid sample, mixing them, subsequently dropping the mixture into reagent 3 containing 90% or more of an organic solvent, and mixing them; (b) stirring at a low temperature the mixed solution obtained in step (a); (c) centrifuging at a low temperature the stirred solution obtained in step (b) and removing the supernatant; (d) adding reagent 4 containing an organic solvent and an acid to the precipitate obtained in step (c) and mixing them; (e) stirring at a low temperature the mixed solution obtained in step (d); and (f) centrifuging at a low temperature the stirred solution obtained in step (e) and recovering the supernatant.

Abstract: This invention relates to substance FKI-3864 represented by the following formula [I] having an inhibitory activity on the synthesis of triacylglycerols and a method for preparing the same. The substance FKI-3864 can be prepared by a method comprising culturing a microorganism which belongs to the genus Penicillium and is capable of producing the substance FKI-3864, and particularly Penicillium pinophilum FKI-3864 (FERM BP-11093) so as to accumulate the substance FKI-3864 in the culture and collecting the substance FKI-3864 from the culture. The substance has an inhibitory activity on the synthesis of intracellular triacylglycerols and is useful for prevention or treatment of obesity.

Abstract: Disclosed is a process for producing an artificial tissue, which comprises a step of providing a liquid flow control member and a mesh member in a flow path through which a cell culture liquid comprising at least one type of animal cells, a collagen-binding cell growth factor and an extracellular matrix component is circulated and cultured to accumulate the extracellular matrix molecule and the animal cells on the surface of the liquid flow control member at a high density, thereby forming a high-density cultured tissue, wherein the liquid flow control member and the mesh member are so arranged in the flow path that these members are in contact with each other or in proximity to each other, and wherein the mesh member is arranged on the back side of the liquid flow control member relative to the direction of the liquid flow. Also disclosed is an artificial tissue produced by the process.

Abstract: Disclosed is a method for detecting the drug effects of DNA methylation inhibitors that detects the drug sensitivity of gene-expressing cells to DNA methylation inhibitors based on gene expression of a transcription factor (PU. 1) and/or gene expression of metallothionein (MT) that participates in differentiation to neutrophil and monocyte lines or based on DNA methylation in the metallothionein (MT) gene promotor region. Hematopoietic tumors can be treated effectively and specifically after predicting the effects of DNA methylation inhibitors on the hematopoietic tumor cells of myelodysplastic syndrome, acute myelocytic leukemia (AML), and other hematopoietic organ diseases, so therapeutic results are improved.

Abstract: An optical coherence tomography apparatus constructs a tomographic image of a measurement object on the basis of a spectral characteristic obtained by spectrally dividing interference light, which combines signal light composed of the measurement light reflected by the measurement object and reference light, using an optical demultiplexer.

Abstract: This invention relates to substance FKI-3864 represented by the following formula [I] having an inhibitory activity on the synthesis of triacylglycerols and a method for preparing the same. The substance FKI-3864 can be prepared by a method comprising culturing a microorganism which belongs to the genus Penicillium and is capable of producing the substance FKI-3864, and particularly Penicillium pinophilum FKI-3864 (FERM BP-11093) so as to accumulate the substance FKI-3864 in the culture and collecting the substance FKI-3864 from the culture. The substance has an inhibitory activity on the synthesis of intracellular triacylglycerols and is useful for prevention or treatment of obesity.

Abstract: The present invention provides compounds which exhibit an inhibitory effect on undecaprenyl diphosphate synthase of microbes and thereby they are expected to be used clinically as pharmaceutical agents for infectious diseases caused by bacteria. The process comprises culturing a microbe belonging to Penicillium and having ability of producing an FKI-3368 substance in or on a nutrient medium to accumulate the FKI-3368 substance in the nutrient medium and collecting the FKI-3368 substance from the culture.

Abstract: An OCT technique that permits tomographic observation of biological body parts that are difficult to restrain, and also provides a tomographic observation technique for the observation of a constrainable part that does not require constraint and thus removes a burden on the biological body. A wavelength-tunable light generator (wavelength-tunable light source) is employed as the light source of the optical coherence tomography device. The wavelength-tunable light generator has a wave number tunable range width of at least 4.7×10?2 ?m?1 and an emitted-light frequency width of no more than 13 GHz, for example, and is capable of changing the wave number stepwise at wave number intervals of no more than 3.1×10?4 ?m?1 and time intervals of no more than 530 ?s.

Abstract: An optical coherence tomography apparatus constructs a tomographic image of a measurement object on the basis of a spectral characteristic obtained by spectrally dividing interference light, which combines signal light composed of the measurement light reflected by the measurement object and reference light, using an optical demultiplexer.

Abstract: The present invention provides an OCT technique that permits tomographic observation of a biological body parts that is difficult to restrain and also provides a tomographic observation technique for the observation of a constrainable part that does not require constraint and remove the burden from biological body. A wavelength-tunable light generator (wavelength-tunable light source) is employed as the light source of the optical coherence tomography device. The wavelength-tunable light generator has a wave number tunable range width of at least 4.7×10?2 ?m?1 and an emitted-light frequency width of no more than 13 GHz, for example, and includes means capable of changing the wave number stepwise at wave number intervals of no more than 3.1×10?4 ?m?1 and time intervals of no more than 530 ?s.

Abstract: The present invention provides an OCT technique that permits tomographic observation of a biological body parts that is difficult to restrain and also provides a tomographic observation technique for the observation of a constrainable part that does not require constraint and remove the burden from biological body. A wavelength-tunable light generator (wavelength-tunable light source) is employed as the light source of the optical coherence tomography device. The wavelength-tunable light generator has a wave number tunable range width of at least 4.7×10?2 ?m?1 and an emitted-light frequency width of no more than 13 GHz, for example, and includes means capable of changing the wave number stepwise at wave number intervals of no more than 3.1×10?4 ?m?1 and time intervals of no more than 530 ?s.